logo
How To Talk Vaccines With Skeptics: 5 Tips From a Doctor

How To Talk Vaccines With Skeptics: 5 Tips From a Doctor

Medscape15-07-2025
Vaccines recommended for children and adolescents are safe and effective and have prevented an estimated 146 million deaths in children under the age of 5 years worldwide. However, many clinicians continue to face questions and concerns from parents and may feel uncertain about how to respond.
In a recent JAMA Insights , Sean T. O'Leary, MD, MPH, professor of Pediatrics at the University of Colorado Anschutz Medical Campus, Aurora, Colorado, and pediatric infectious disease specialist at Children's Hospital Colorado, outlined five strategies to help physicians build trust and support informed vaccination decisions.
Tip 1: Understanding Vaccine Hesitancy
Most individuals who question vaccines do not intend to cause harm. Acknowledging this shared concern lays a respectful foundation. For example, 'We both want what is best for your child — keeping them healthy and protected.' This is the most important thing to recognize when communicating with families about vaccination.
Tip 2: Effective Communication Strategies
For parents who resist an initial presumptive recommendation, clinician responses can shape the outcome of the conversation. A statement such as 'It's time for Maya's vaccines today' normalizes vaccination as routine medical care, whereas a question like 'What do you think about vaccines today?' indicates that vaccination is optional, potentially reinforcing doubt.
Tip 3: Values-based messaging
Many vaccine-hesitant parents value natural approaches to their health and personal autonomy. Instead of positioning vaccines in opposition to these values, clinicians can frame immunizations to support a child's natural defenses and protect them from serious illnesses. Vaccine conversations should be ongoing and not one-off. Parents who initially decline may change their minds if they consistently hear the same message from a trusted clinician. Gentle persistence, combined with respect for parental decision-making, can lead to higher vaccine uptake.
Tip 4: Pre-bunk Misinformation
Another effective technique is pre-bunking, which involves addressing false information before parents encounter it. Cautioning parents during well-baby visits about inaccurate sources of information can reduce the influence of false claims on vaccination. For example, a clinician might say, 'There is a lot of inaccurate information about vaccines out there that can make vaccines seem unnecessary or even scary. I have some good sources of information I recommend.' By proactively pre-bunking unreliable information, clinicians can prevent parents from being swayed by misleading narratives.
Tip 5: Motivational interviewing
Instead of simply stating that vaccines are safe, clinicians can strengthen confidence by using motivational interviewing techniques to explain the rigorous safety testing that vaccines undergo before approval, that vaccines are removed from the market if serious safety concerns arise, and that robust surveillance systems are in place to monitor adverse events. Inserting a simple statement, such as 'I have heard that concern before and I have looked into it. Would you mind if I share with you what I found out?' may make parents more receptive to subsequent shared factual information.
Effective communication strategies can help clinicians build trust, navigate difficult vaccine conversations, strengthen parents' intentions to vaccinate, and improve vaccine uptake.
Conclusion
A presumptive approach presenting vaccination as the norm, combined with listening to parents' concerns, motivational interviewing, and pre-bunking unreliable information, can improve vaccine acceptance. Building trust through clear explanations, aligning messages with parental values, and leveraging social norms further strengthens vaccine confidence. Although some parents may not immediately accept vaccines, ongoing dialogue and consistent messaging can increase the likelihood of their eventual acceptance. Using these communication strategies, clinicians can help ensure that more children receive life-saving vaccines, thereby protecting both individual and public health.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The president vows to slash medication cost to an unachievable degree.
The president vows to slash medication cost to an unachievable degree.

Yahoo

time7 minutes ago

  • Yahoo

The president vows to slash medication cost to an unachievable degree.

President Donald Trump has promised to reduce American drug prices by mathematically impossible figures of up to '1400 percent.' Speaking during a White House event attended by Republican members of Congress and his Cabinet, Trump said he would tackle the long-running issue of high medication costs in the U.S. But Trump did not set any achievable targets for that aim, instead outlining a range of percentages which would yield negative prices, meaning drug companies would have to pay people to take their medications.

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

Yahoo

time7 minutes ago

  • Yahoo

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates
U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

Yahoo

time7 minutes ago

  • Yahoo

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

HOUSTON, July 23, 2025--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three months and six months ended June 30, 2025, on Wednesday, August 6, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 7, 2025. Conference Call Date: Thursday, August 7, 2025 Time: 10:30 am Eastern / 9:30 am Central Dial-In Number: (800) 343-4136 Primary or (203) 518-9843 Alternate Conference ID: USPHQ225 (In order to join this conference call,you will be required to provide the Conference ID listed above) To participate, please call in 15 minutes prior to start time. To listen to the live call, please go to and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025 at USPH's website. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 768 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release. View source version on Contacts U.S. Physical Therapy, Hendrickson, Chief Financial OfficerEmail: Chendrickson@ Chris Reading, Chief Executive Officer(713) 297-7000 Three Part AdvisorsJoe Noyons(817) 778-8424

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store